MA41809A - Biotine pour le traitement de la sclérose latérale amyotrophique - Google Patents
Biotine pour le traitement de la sclérose latérale amyotrophiqueInfo
- Publication number
- MA41809A MA41809A MA041809A MA41809A MA41809A MA 41809 A MA41809 A MA 41809A MA 041809 A MA041809 A MA 041809A MA 41809 A MA41809 A MA 41809A MA 41809 A MA41809 A MA 41809A
- Authority
- MA
- Morocco
- Prior art keywords
- biotin
- treatment
- lateral sclerosis
- amyotrophic lateral
- nmo
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 2
- 229960002685 biotin Drugs 0.000 title abstract 2
- 235000020958 biotin Nutrition 0.000 title abstract 2
- 239000011616 biotin Substances 0.000 title abstract 2
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Magnetic Ceramics (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Farming Of Fish And Shellfish (AREA)
Abstract
L'invention concerne l'utilisation de la biotine pour le traitement de la sclérose latérale amyotrophique, ainsi que pour les neuropathies périphériques démyélinisantes et la neuromyélite optique (nmo).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (fr) | 2015-03-26 | 2015-03-26 | Biotin pour le traitement de la sclérose latérale amyotrophique |
| PCT/EP2016/056696 WO2016151132A1 (fr) | 2015-03-26 | 2016-03-25 | Biotine pour le traitement de la sclérose latérale amyotrophique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41809A true MA41809A (fr) | 2018-01-30 |
| MA41809B1 MA41809B1 (fr) | 2019-12-31 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41809A MA41809B1 (fr) | 2015-03-26 | 2016-03-25 | Biotine pour le traitement de la sclérose latérale amyotrophique |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (fr) |
| EP (2) | EP3072513A1 (fr) |
| JP (1) | JP6752874B2 (fr) |
| KR (1) | KR20170131543A (fr) |
| CN (2) | CN111973592A (fr) |
| AU (1) | AU2016238759B2 (fr) |
| BR (1) | BR112017020408A2 (fr) |
| CA (1) | CA2980660A1 (fr) |
| CY (1) | CY1122374T1 (fr) |
| DK (1) | DK3273957T3 (fr) |
| EA (1) | EA034394B1 (fr) |
| ES (1) | ES2748354T3 (fr) |
| HR (1) | HRP20191491T1 (fr) |
| HU (1) | HUE046116T2 (fr) |
| IL (1) | IL254619B (fr) |
| LT (1) | LT3273957T (fr) |
| MA (1) | MA41809B1 (fr) |
| ME (1) | ME03567B (fr) |
| PL (1) | PL3273957T3 (fr) |
| PT (1) | PT3273957T (fr) |
| RS (1) | RS59149B1 (fr) |
| SI (1) | SI3273957T1 (fr) |
| SM (1) | SMT201900548T1 (fr) |
| WO (1) | WO2016151132A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (fr) | 2015-03-26 | 2016-09-28 | Medday | Biotin pour le traitement de la sclérose latérale amyotrophique |
| EP3275439A1 (fr) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Procédé de traitement de l'encéphalopathie hépatique |
| CA3121634A1 (fr) * | 2018-12-11 | 2020-06-18 | Myospots Australia Pty Ltd | Tampon adhesif |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
| US20240082296A1 (en) * | 2020-10-09 | 2024-03-14 | Tx Medic Ab | Treatment of muscle atrophy using dextran sulfate |
| WO2023081458A1 (fr) * | 2021-11-08 | 2023-05-11 | Rutgers, The State University Of New Jersey | Systèmes et procédés pour le diagnostic et/ou le traitement d'une neuropathie démyélinisante |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| DK1575531T3 (da) | 2002-09-27 | 2011-11-21 | Biogen Idec Inc | Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| EP2515863A2 (fr) | 2009-12-23 | 2012-10-31 | Lupin Limited | Compositions pharmaceutiques d'ilopéridone à libération lente |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| EP2699256B1 (fr) * | 2011-04-21 | 2017-09-27 | The Regents of the University of Colorado, a body corporate | Compositions et méthodes de traitement de maladie de devic |
| CN109316480A (zh) * | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| WO2014177286A1 (fr) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotine pour son utilisation dans le traitement d'une adrénoleucodystrophie liée à l'x |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (fr) | 2015-03-26 | 2016-09-28 | Medday | Biotin pour le traitement de la sclérose latérale amyotrophique |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/fr not_active Ceased
-
2016
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko not_active Withdrawn
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/fr not_active Ceased
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/fr active Active
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 CA CA2980660A patent/CA2980660A1/fr not_active Abandoned
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 SM SM20190548T patent/SMT201900548T1/it unknown
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/fr unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3021970B1 (fr) | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs | |
| MA41809B1 (fr) | Biotine pour le traitement de la sclérose latérale amyotrophique | |
| MA40576A (fr) | Anticorps et immunoconjugués anti-her2 | |
| MA41013A (fr) | Compositions comprenant des souches bactériennes | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3642667C0 (fr) | Lentille de contact d'orthokératologie pour le traitement de la myopie | |
| MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| MA71420A (fr) | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaîne légère et d'autres tumeurs malignes hématologiques positives à cd38 | |
| MA44659B1 (fr) | Anticorps anti-tim-3 et compositions | |
| MA44322A (fr) | Compositions comprenant des souches bactériennes | |
| MA41060B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA55434B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA43187B1 (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| MA43018B1 (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA39095A1 (fr) | Anticorps et immunoconjugués anti-cd33 | |
| MA41010B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA52216B1 (fr) | Mirikizumab pour le traitement de la colite ulcéreuse | |
| EP3645040A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers | |
| MA38827A1 (fr) | Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
| EP3442562A4 (fr) | Utilisation d'il-22 pour le traitement de l'entérocolite nécrosante | |
| FR3019465B1 (fr) | Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen | |
| MA42419B1 (fr) | Méthode de traitement de l'encéphalopathie hépatique |